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INTRODUCTION
 Hepatocellular carcinoma (HCC) is the most 
common tumor of liver parenchyma and the 
fifth most common cancer in the world.1 The 
epidemiological distribution of HCC varies across 
the globe being the highest in south East Asia and 
sub-Saharan Africa.2 Chronic liver disease (CLD) 
and HCC are the consequences of viral hepatitis 
and nearly 17 million in people in Pakistan are 
affected by viral hepatitis.3
 Liver transplantation (LT) is treatment of choice 
for CLD and localized hepatocellular carcinoma.4 
The commonest cause of death in patients with HCC 
is extra-hepatic metastasis which is usually multifo-
cal.5 Surgical resection offers a unique opportunity 
for solitary metastasis after LT.5 To our knowledge 
solitary adrenal metastasis is a rare finding and the 
available data is limited to few case reports and 
there is no consensus on its management. Herein, 
we report a case of right adrenal metastasis of HCC 
fifteen month post LT, patients is alive and doing 
well 24 months after adrenalectomy.
CASE REPORT
 A 61-year-old gentleman with controlled diabetes 
mellitus and 13 years history of hepatitis C and 
chronic liver disease underwent live non related 
LT in October 2012 in China for hepatocellular 
carcinoma lesion measuring 3.5cm on preoperative 
imaging. The pre-operative serum alpha fetoprotein 
(AFP) values were within normal limits. Final 
histopathology of resected liver showed a focus of 
hepatocellular carcinoma grade II, with tumor size 
of 3 cm without any major vascular involvement. 
He did not receive any pre or post-transplant 
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ABSTRACT
Liver transplantation (LT) is the treatment of choice for localized hepatocellular carcinoma (HCC) associated 
with cirrhosis. Extra hepatic metastasis is the most common cause of death in these patients. There is very 
little evidence regarding the natural history and treatment options for patients developing HCC recurrence 
after LT. Surgical resection offers a unique opportunity for solitary metastasis. We report a 61 year old male 
with solitary right adrenal metastasis 15 months post LT which was managed with open adrenalectomy. 
The patient is alive and disease free 24 months after the surgery. The case, histo-pathological findings and 
literature review is discussed.
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chemotherapy. Immunosuppressant treatment 
comprised of FK506 2.5mg and  mycophenolate 
mofetil (Celcept) 750mg twice daily 
 Unfortunately, the  patient did not follow a 
standardized surveillance protocol and was referred 
to us fifteen months post LT with an ultrasound 
scan revealing a right adrenal mass with normal 
serum AFP (1.0 IU/ml). He denied any history of 
weight loss, abdominal pain or hyper adrenergic 
symptoms. Contrast enhanced computerized 
tomography (CT) of chest and abdomen showed 
normal transplanted liver and an enhancing right 
adrenal mass with central necrosis measuring 
30 x 33 x 55 mm without any evidence of distant 
disease (Fig.1). A positron emission tomography 
(PET) scan confirmed the hyper metabolic lesion, 
raising suspicion of malignancy with standardized 
uptake value (SUV) of 4.5. The metabolic work-
up was negative for pheochromocytoma, Cushing 
syndrome and Conn’s syndrome.
 He underwent a right open adrenalectomy 
in March 2014 through right flank incision and 
histopathology revealed metastatic HCC with 
angio-lymphatic invasion (Fig.2). The patient made 
good recovery and was discharged. However he 
was advised to switch to Everolimus from FK506 
as it decreases chances of HCC recurrence. After 
almost 39 months post-transplant he is doing well 
and under close surveillance.
DISCUSSION
 Liver transplantation (LT) is currently the best 
available option for select cases of HCC with cirrho-
sis and has shown to improve the overall survival.4 
A careful follow up is needed in these patients due 
to possibility of recurrence not only in the graft 
but also in extra-hepatic organs.1 The recurrence of 
HCC after liver transplant is reported to be as high 
as 10%, with studies reporting most of extra hepatic 
recurrence within first year of transplant.6,7
 There is very little evidence in literature regard-
ing the natural history, effects of medical or surgi-
cal treatment and predictors of survival in patients 
who develop HCC recurrence after LT. Manage-
ment of single site metastasis of HCC after LT lacks 
the consensus but certainly depends on various 
factors like, site, size of tumor, tumor resectability, 
patient’s functional status, comorbid medical con-
ditions, biochemical markers (AFP) and presence or 
absence of HCC in the transplanted liver.8
 In clinical practice, adrenal gland is an uncommon 
site of metastasis from HCC with incidence ranging 
from 1- 2.4%. Few autopsy reports have showed 
that it is the second site of hematogenous spread 
from HCC after lung, with reported incidence of 
8.4%.9
 The experience of surgical excision (adrenalecto-
my) for metastasis is limited to mainly case reports 
and these lesions can also be managed with other 
non-surgical modalities. Combined Radiofrequen-
cy ablation (RFA) with trans-arterial chemoemboli-
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Fig.1: Axial images of contrast enhanced CT, showing 
normal transplanted liver, spleen, left kidney and right 
adrenal mass abutting liver (arrow).
Fig.2: A: Tumour cells infiltrating into the normal 
adrenal gland parenchyma at the periphery H&E, 100 
xM). B: Large lobules of neoplastic cells surrounded by 
rich sinusoidal network. Intracytoplasmic eosinophilic 
inclusions are also seen in large size, polygonal cells 
(H&E, 400 x M). C: Tumor cells (Right) staining positive 
for Cytokeratin CAM5.2 immunohistochemical stain 
while normal adrenal tissue (Left) are negative (200xM). 
D: Diffuse Hep-par1 positive immunohistochemical stain 
membranes and cytoplasmic (left) while normal adrenal 
tissue (right) is negative (H&E, 400 xM).
zation (TACE) was described in a series from Japan 
for adrenal metastasis from HCC and showed it to 
be a safe option which can lengthen survival.9
 In an analysis of 30 patients who had adrenal 
metastasis from HCC, Park JS et al.10 reported adre-
nalectomy in five patients, non-surgical treatment 
such as TACE or chemo + radiation therapy in 19 
patients. Six patients did not receive any treatment. 
They reported a median survival of 11 months. 
They also observed that the incidence of metasta-
sis is higher on the right adrenal gland compared 
to left side. They concluded that adrenalectomy for 
metastatic HCC results in improved patient surviv-
al especially those in good general condition.
 In a recently published study from Korea, Ha 
TY et al.11 studied 26 patients with metachronous 
adrenal metastasis  in patients who underwent 
liver resection (19 patients) or LT (7 patients). All 
patients had adrenal recurrence within 18 months 
and underwent adrenalectomy. The mean diameter 
of tumor was 3.4±1.8 cm in LT group. The five year 
survival after adrenalectomy was 20.3%.Our case 
was found to have HCC of resected liver following 
transplantation and had metachronous adrenal 
metastasis 15 months post LT which was managed 
successfully by surgical excision.
 Recurrence after LT does reduce overall survival. 
Several factors have been identified that contribute 
to increased recurrence and affect the survival. 
These include >1 tumor, size > 5 cm and recurrence 
within one year.9
 Uka K et al.12 reported a cumulative survival rate 
of 21.7%, 14.2% and 7.1% respectively one, two and 
three years after the initial diagnosis of extra hepatic 
metastasis in patients with HCC with a median sur-
vival of 4.9 months (range, 0-37 months). Roayaie S 
et al. in their series have shown that patients who 
undergo resection or ablation of a recurrence had 
that.8
 Serum AFP is a good indicator for HCC 
metastasis.7 Our case was unique in that it had 
normal serum AFP levels both before the LT and 
after adrenal metastatic despite of considerable 
sized tumor. The patient is presently alive and 
disease free.  He is under regular surveillance with 
CT /PET scan along with tumor marker.
CONCLUSION
 We believe that surgical excision (adrenalectomy) 
should be considered for selected LT patients 
with solitary adrenal metastasis from HCC. 
Further evidence is needed to develop definite 
recommendations.
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